# INDUCE-1 (NCT02723955)

> Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02723955
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: GlaxoSmithKline
- Conditions: Neoplasms
- Interventions: feladilimab (GSK3359609); GSK3174998; Pembrolizumab; Docetaxel; Pemetrexed; Paclitaxel plus Carboplatin; Gemcitabine plus Carboplatin; Fluorouracil (5-FU) plus carboplatin or cisplatin; Dostarlimab; Cobolimab; Bintrafusp alfa
- Enrollment: 829
- Primary outcome: Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
- Primary outcome: Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)
- Primary outcome: Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- Primary outcome: Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
- Primary outcome: Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- Primary outcome: Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
- Primary outcome: Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
- Primary outcome: Part 1A: Number of Participants With Dose Modifications of Feladilimab
- Primary outcome: Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
- Primary outcome: Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)
- Primary outcome: Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters
- Primary outcome: Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline
- Primary outcome: Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters
- Primary outcome: Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline
- Primary outcome: Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline
- Primary outcome: Part 2A: Number of Participants With Dose Modifications of Feladilimab

## Indexed commentary on INDUCE-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=induce-1-nct02723955